LOGIN  |  REGISTER
Viking Therapeutics
Terns Pharmaceuticals

Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2025 Results

February 07, 2025 | Last Trade: US$31.66 0.89 -2.73

ALL-REMOTE COMPANY/WILMINGTON, Del. / Feb 07, 2025 / Business Wire / Phreesia, Inc. (NYSE: PHR) (“Phreesia”) today announced that it will release its fiscal fourth quarter and fiscal year 2025 financial results after the close of market trading on Wednesday, March 12, 2025. Phreesia will issue a press release announcing its quarterly and full year results and the company’s quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal fourth quarter and fiscal year 2025 results starting at 5PM Eastern Time on the same day.

To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or visit the “Events & Presentations” section of ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

ABOUT PHREESIA

Phreesia is a trusted leader in patient activation, giving providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page